GILOTRIF vs ROZLYTREK

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 18, 2026·How we rate

Possible drug interaction. GILOTRIF and ROZLYTREK are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	GILOTRIF	ROZLYTREK
Rating	72/100	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	AFATINIB DIMALEATE	ENTRECTINIB
Manufacturer	Boehringer Ingelheim	Genentech Inc
Dosage forms	Tablet	Capsule, Oral pellets
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma	Non-Small-Cell Lung Carcinoma

gilotrif rozlytrek

Rating

72/100

70/100

Pharmacy pays

—

Type

Active ingredient

AFATINIB DIMALEATE

ENTRECTINIB

Manufacturer

Boehringer Ingelheim

Genentech Inc

Dosage forms

Tablet

Capsule, Oral pellets

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma

Non-Small-Cell Lung Carcinoma

Frequently asked questions

Which is better-rated, Gilotrif or Rozlytrek?

By our independent rating, Gilotrif scores higher — 3.6 vs 3.5 out of 5 for Rozlytrek. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Gilotrif and Rozlytrek?

Gilotrif contains Afatinib Dimaleate, while Rozlytrek contains Entrectinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.